Solid Biosciences Reports Posisitve Initial Data From 1/2 INSPIRE DUCHENNE Study; Stock Up

(RTTNews) - Solid Biosciences Inc. (SLDB) Tuesday reported positive initial data from the Phase 1/2 INSPIRE DUCHENNE study of its gene therapy product candidate SGT-003 for the treatment of Duchenne muscular dystrophy. Following the news, the company's shares were more than 75 percent up in pre-market.

In the study, SGT-003 was administered as a one-time intravenous infusion in 6 participants, as of February 11, 2025. Interim data reported in the first three participants showed an average microdystrophin expression of 110%. Microdystrophin expression is a measure of the production of a shortened, functional gene that's used to treat Duchenne. Significant improvements in multiple additional muscle health biomarkers were also observed.

The company plans to dose about 20 participants by the fourth quarter of 2025.

Solid Biosciences stock had closed at $4.03, up 2.28 percent on Friday. It has traded in the range of $2.88 - $15.05 in the last 1 year.